ADX-248, which replaces ADX-743, is being developed for the treatment of metabolic inflammation, including obesity and hypertriglyceridemia
The FDA’s review also revealed delays in Philips’ internal investigations, with 54 inquiries failing to meet targeted completion dates—23 of which were delayed by more than 100 days
Approval based on pivotal KOMET Phase III trial demonstrating significant tumour reduction in adults with NF1
The EIR was issued with an inspection classification of Voluntary Action Indicated (VAI) post the inspection conducted in June 2025
Test delivers results in just 18 minutes, enabling faster laboratory workflows and patient management during outbreaks
Sotyktu continues to demonstrate consistent efficacy and safety across rheumatic conditions
Allergan Aesthetics reaffirms commitment to empowering girls through STEM mentorship and education initiatives
The Fast Track Designation was supported by nonclinical data as well as clinical results from the ongoing Phase I/IIa trial evaluating the safety and tolerability
The company's net income attributable to equity holders dropped to €2.80 billion from €2.82 billion last year
Subscribe To Our Newsletter & Stay Updated